BioVaria 2025

BioVaria 2025

ABOUT BIOVARIA

BioVaria targets technology scouts, business developers and investors highlighting commercially attractive licensing opportunities and promising startups from across Europe.

This unique event brings together Europe‘s leading tech transfer professionals, innovators from academia and start-ups with investors and representatives of the global biotech and pharma industry.

//

  • Scientists, technology transfer professionals, investors and industry scouts
  • European technology transfer organizations presenting commercially attractive licensable technologies and partnership opportunities
  • Startup Pitch & Partner featuring some of Europe’s most promising startups
  • Face-to-face discussions with investors and inventors

STARTUP PITCH & PARTNER

The interactive BioVaria Startup Pitch & Partner Programme offers start-ups from all life-science areas (pharma, diagnostics, medtech and digital health)

  • the possibility to present their technology and business concept
  • direct exchange with potential VCs and investors during speed dating
  • the opportunity to network with representatives of the industry and the life science scene

Applications are open to pre- and post-seed start-ups. Start-ups selected by an expert jury of investors will then compete live on the BioVaria stage for a “BioVaria Startup Award” worth up to 2,000 euros.

The application deadline for start-ups is February 14, 2025.

The application form can be found on our website: https://www.biovaria.org/startup-pitch-partner/startup-pitch-partner

register now

Our latest News

discover more
RHEACELL receives EMA approval for allo-APZ2-CVU Phase 3 trial in chronic venous ulcers

RHEACELL receives EMA approval for allo-APZ2-CVU Phase 3 trial in chronic venous ulcers

Heidelberg, Germany, 19.12.2024 – RHEACELL today received approval from the European Medicines Agency (EMA) for its blinded, multi-centric Phase-3 trial (NCT06489028) evaluating allo-APZ2-CVU in patients with chronic venous ulcers (CVU). The pivotal trial will be conducted at more than 100 sites and is expected to enroll 250 patients, starting enrollment in Europe in Q1 2025. […]

Common cough syrup ingredient shows promise in treating serious lung disease

Common cough syrup ingredient shows promise in treating serious lung disease

EMBL scientists discover that an FDA-approved, over-the-counter cough syrup ingredient has potential to treat fibrotic lung disease. Summary A common over-the-counter ingredient in many cough syrups may have a greater purpose for people suffering from lung fibrosis that is related to any number of serious health conditions.  Scientists from EMBL Heidelberg were part of a […]

Antibody that Neutralizes Inhibitory Factors Involved in Nerve Regeneration Leads to Enhanced Motor Function after Acute Spinal Cord Injury

Antibody that Neutralizes Inhibitory Factors Involved in Nerve Regeneration Leads to Enhanced Motor Function after Acute Spinal Cord Injury

Antibodies can improve the rehabilitation of people with acute spinal cord injury. Researchers at 13 clinics in Germany, Switzerland, the Czech Republic and Spain have investigated this with promising results. For the first time, it was possible to identify patient groups that displayed a clinically relevant treatment effect. A follow-up study will start in December […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp